Publications by authors named "Tamon Nagashima"

Claim this Profile
A
A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases.
Ken Sato, Atsushi Naganuma, Tamon Nagashima, Yosuke Arai, Yuka Mikami

Biomedicines· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately.
Hiroki Tojima, Satoru Kakizaki, Satoshi Takakusagi, Takashi Hoshino, Atsushi Naganuma, Tamon Nagashima

Intern Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Takashi Ueno

Oncology· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Atsushi Hiraoka, Takashi Kumada, Takeshi Hatanaka, Toshifumi Tada, Kazuya Kariyama, Tamon Nagashima

Hepatol Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Takeshi Hatanaka, Atsushi Naganuma, Mitsuhiko Shibasaki, Tatsuya Kohga, Yosuke Arai, Tamon Nagashima

Oncology· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment.
Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Takashi Ueno

Cancers (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Hiroki Tojima, Satoru Kakizaki, Satoshi Takakusagi, Takashi Hoshino, Atsushi Naganuma, Tamon Nagashima

Hepatol Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study.
Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Hiroki Tojima

Hepatol Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Takeshi Hatanaka, Satoru Kakizaki, Daisuke Uehara, Tamon Nagashima, Takashi Ueno

Intern Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.
Ken Sato, Atsushi Naganuma, Tamon Nagashima, Takashi Hoshino, Daisuke Uehara

Hepatol Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Right aortic arch with mirror image branching and vascular ring.
Yasutomi Higashikuni, Tamon Nagashima, Nobukazu Ishizaka, Koichiro Kinugawa, Yasunobu Hirata

Int J Cardiol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis